FDMT: 4D Molecular Therapeutics, Inc. Common Stock Company Profile & Statistics

4D Molecular Therapeutics, Inc. Common Stock Profile

About

4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted and evolved adeno-associated viruses vectors. It offers a portfolio of gene therapy product candidates focusing on the ophthalmology, cardiology and pulmonology therapeutic areas. 4D Molecular Therapeutics Inc. is based in Emeryville, California.

Info & Links

CEO

David Kirn

Headquarters

5858 HORTON STREET #455
EMERYVILLE, CA 94608, UNITED STATES

Auditor

PricewaterhouseCoopers LLP

Share holders

Employees

227

4D Molecular Therapeutics, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization²

533.53M

Enterprise Value

456.37M

Enterprise Value/EBITDA(ttm)

-2.05

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

16.94K

Price to Book(mrq)

1.32

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

75.00%

Operating Margin(ttm)

-594375.81%

Profit Margin(ttm)

-542119.20%

Return on Equity(ttm)

-40.15%

Return on Invested Capital(ttm)

-40.86%

Return on Assets(ttm)

-36.43%

Income Statement

Revenue(ttm)

33.00K

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

33.00K

EBITDA(ttm)³

-222.35M

Net Income Available to Common(ttm)

-196.14M

Diluted EPS(ttm)

-3.53

Share Statistics

Beta (5Y Monthly)

2.93

52-Week Change

38.33%

S&P 500 52-Week Change

17.35%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

46.70M

Dividend Yield

0.00%

Float⁴

42.22M

% Held by Insiders

9.60%

% Held by Institutions

99.27%

Balance Sheet

Total Cash(mrq)

293.23M

Total Cash Per Share(mrq)

6.28

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

8.75%

Quick Ratio(mrq)

8.75%

Book Value Per Share(mrq)

9.01

Cash Flow

Operating Cash Flow Per Share(ytd)

-1.63

Free Cash Flow(ytd)

-91.83M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

FDMT

4D Molecular Therapeutics, Inc. Common Stock